Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy

March 19, 2024 By The ASCO Post Staff

Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as second- or third-line treatment. According to Dr. Slomovitz, this agent may be considered a potential new standard of care in this population.

Related Content